Program
BNT166A
A development code. Also written as “BNT166a”.
Its studies are mostly in Mpox, Monkeypox, led by BioNTech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioNTech | 21 open or running | phase 2since Aug 4, 2023 | Aug 4, 2023 | Jun 2027phase 2 · NCT07379580 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 4, 2023First study: phase 2 study in Mpox, MonkeypoxFirst studyNCT05988203 · 96 enrolled · United States, United Kingdom
- Jan 23, 2026Phase 2 study in Mpox, MonkeypoxNCT07379580 · 310 planned · Democratic Republic of the Congo, South Africa
Ahead
- Jun 2027Primary completion: phase 2 study in Mpox, MonkeypoxNCT07379580
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07379580Mpox, Monkeypox · Democratic Republic of the Congo, South Africa | 2 | Recruiting | Jun 2027 | 310 |
| NCT05988203Mpox, Monkeypox · United States, United Kingdom | 2 | Completed | Aug 25, 2025 | 96 |
How it is read
Names in the registry
- “BNT166a”, 2 entries
Codes read as this program: BNT166A.
Conditions, from the studies’ own filings
- Mpox, Monkeypox, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.